Trevi Therapeutics (TRVI) Scheduled to Post Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) is scheduled to be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Trevi Therapeutics to post earnings of ($0.11) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trevi Therapeutics Price Performance

Shares of Trevi Therapeutics stock traded up $0.04 during trading hours on Tuesday, reaching $2.65. The company’s stock had a trading volume of 100,654 shares, compared to its average volume of 250,764. The firm has a 50 day moving average price of $2.76 and a 200-day moving average price of $2.68. Trevi Therapeutics has a one year low of $0.97 and a one year high of $4.00. The stock has a market cap of $186.64 million, a P/E ratio of -7.59 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TRVI shares. Rodman & Renshaw started coverage on shares of Trevi Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 8th.

Insider Buying and Selling

In related news, insider Thomas Sciascia sold 53,368 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $2.55, for a total transaction of $136,088.40. Following the completion of the transaction, the insider now owns 214,433 shares in the company, valued at approximately $546,804.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Thomas Sciascia sold 53,368 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $2.55, for a total value of $136,088.40. Following the sale, the insider now directly owns 214,433 shares of the company’s stock, valued at approximately $546,804.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jennifer L. Good sold 25,037 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $2.86, for a total transaction of $71,605.82. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $610,075.18. The disclosure for this sale can be found here. Insiders sold a total of 87,333 shares of company stock worth $232,454 in the last 90 days. 24.37% of the stock is owned by corporate insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.